Spots Global Cancer Trial Database for metastatic pancreatic cancer
Every month we try and update this database with for metastatic pancreatic cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | NCT04229004 | Metastatic Panc... Metastatic Panc... | Gemcitabine com... Dose -mFOLFIRIN... Dose - Pamrevlu... Dose- Canakinum... Drug: Dose -SM-... | 18 Years - | Pancreatic Cancer Action Network | |
| Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY | NCT04789980 | Locally Advance... Metastatic Panc... | 19 Years - | Boryung Pharmaceutical Co., Ltd | ||
| Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer. | NCT05360745 | Quality of Life Locally Advance... Metastatic Panc... | ARACOMPLEX® placebo | 18 Years - 75 Years | Fundacion para la Excelencia y la Calidad de la Oncologia | |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer | NCT00630552 | Adenocarcinoma ... Metastatic Panc... Pancreatic Canc... | Placebo AMG 479 AMG 655 | 18 Years - | NantCell, Inc. | |
| Treatment of Pancreatic Cancer With Abraxane | NCT02555813 | Metastatic Panc... | Abraxane Gemcitabine | 18 Years - | Celgene | |
| Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | NCT00844649 | Metastatic Panc... | Albumin-bound p... Gemcitabine | 18 Years - 79 Years | Celgene | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Project Survival-Prospective Biomarker Discovery | NCT02781012 | Pancreatic Neop... Pancreatic Canc... Pancreatitis Pancreatic Aden... Metastatic Panc... | 18 Years - | Pancreatic Cancer Research Team | ||
| Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | NCT06353581 | Locally Advance... Metastatic Panc... | Neulapeg Control | 19 Years - | Yonsei University | |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | NCT01934634 | Metastatic Panc... | LCL161 Gemcitabine nab-Paclitaxel | 18 Years - | US Oncology Research | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer | NCT01946646 | Metastatic Panc... | S-1-CCRT | 20 Years - 79 Years | National Taiwan University Hospital | |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | NCT00042939 | Pancreatic Canc... | cetuximab docetaxel irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity | NCT03821870 | Metastatic Panc... | Inditreat Experimental dr... | 18 Years - | Vejle Hospital | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | NCT03435289 | Pancreatic Canc... Metastatic Panc... | CPI 613 in Comb... | 18 Years - | Atlantic Health System | |
| Post Marketing Surveillance Study for ONIVYDE® in South Korea | NCT03446872 | Metastatic Panc... | ONIVYDE 5-fluorouracil Leucovorin | 19 Years - | Servier | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | NCT00372944 | Pancreatic Canc... | AZD6244 capecitabine | 18 Years - | AstraZeneca | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | NCT06361888 | Metastatic Panc... | Surufatinib Com... Nab-paclitaxel ... Surufatinib wit... | 18 Years - 75 Years | Hutchmed | |
| Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer | NCT02921646 | Metastatic Panc... | Measure of rest... | 18 Years - | Center Eugene Marquis | |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | NCT06390059 | Metastatic Panc... | Tumor Treating ... Atezolizumab Gemcitabine nab-paclitaxel | 18 Years - | NovoCure Ltd. | |
| Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | NCT00222469 | Metastatic Panc... | bevacizumab gemcitabine oxaliplatin | 18 Years - | University of Oklahoma | |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | NCT05026905 | Phase II, Open-... | Gemcitabine 100... Nab paclitaxel S1 leucovorin Oxaliplatin | 20 Years - | National Health Research Institutes, Taiwan | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | NCT04753879 | Metastatic Panc... | Nab-paclitaxel Gemcitabine Cisplatin Irinotecan Capecitabine Pembrolizumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | NCT01523457 | Metastatic Panc... Pancreatic Canc... | Folfirinox | 18 Years - | Yale University | |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | NCT03602885 | Metastatic Panc... Unresectable Pa... Metastatic Colo... | Usual chemother... Chemotherapy ed... | 21 Years - | Dana-Farber Cancer Institute | |
| A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer | NCT00383149 | Metastatic Panc... | Ixabepilone Cetuximab | 18 Years - | R-Pharm | |
| A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | NCT00726037 | Metastatic Panc... | Ontak | 18 Years - | Loyola University | |
| A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer | NCT05657743 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... Pancreatic Aden... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity | NCT03821870 | Metastatic Panc... | Inditreat Experimental dr... | 18 Years - | Vejle Hospital | |
| Azacitidine and Pembrolizumab in Pancreatic Cancer | NCT03264404 | Pancreas Cancer | Pembrolizumab Azacitidine | 18 Years - | Columbia University | |
| Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | NCT04046887 | Pancreatic Canc... Pancreatic Duct... | Lonsurf Gemcitabine Nab-Paclitaxel | 18 Years - | Indiana University | |
| Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer | NCT01303029 | Metastatic Panc... | Gemcitabine+erl... Gemcitabine+erl... | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | NCT03376659 | Metastatic Colo... Colorectal Aden... Pancreatic Aden... Metastatic Panc... | Durvalumab CV301 Capecitabine Bevacizumab | 18 Years - | Georgetown University | |
| A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | NCT03261947 | Metastatic Panc... Colorectal Canc... Esophageal Neop... Carcinoma, Non-... | TAK-931 | 18 Years - | Takeda | |
| Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer | NCT04112836 | Pancreatic Canc... Exocrine Pancre... Metastatic Panc... Chemotherapy Malnutrition Locally Advance... | 18 Years - | Moscow Clinical Scientific Center | ||
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer | NCT04901741 | Metastatic Panc... | Olaptesed pegol Pembrolizumab | 18 Years - | TME Pharma AG | |
| Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer | NCT05766748 | Metastatic Panc... | Azeliragon | 18 Years - 80 Years | Cantex Pharmaceuticals | |
| Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | NCT02340117 | Metastatic Panc... | SGT-53 nab-paclitaxel Gemcitabine | 18 Years - | SynerGene Therapeutics, Inc. | |
| Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel | NCT03666832 | Metastatic Panc... | TEW-7197 | 19 Years - | Samsung Medical Center | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | NCT03435289 | Pancreatic Canc... Metastatic Panc... | CPI 613 in Comb... | 18 Years - | Atlantic Health System | |
| Patient Reported Outcomes Registry in Patient With Cancer Cachexia | NCT02983500 | Metastatic Panc... NSCLC, Metastat... | 18 Years - | iOMEDICO AG | ||
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024 | Advanced Solid ... Metastatic Colo... Metastatic Panc... | BKM120 mFOLFOX6 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | NCT06353581 | Locally Advance... Metastatic Panc... | Neulapeg Control | 19 Years - | Yonsei University | |
| Study of OB-002 in Patients With Refractory Metastatic Cancer | NCT05940844 | Metastatic Canc... Metastatic Colo... Metastatic Panc... Metastatic Gast... Metastatic Brea... Metastatic Urot... | OB-002 | 18 Years - | Orion Biotechnology Polska Sp. z o.o. | |
| A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | NCT06199466 | Metastatic Panc... | Gemcitabine Nab-paclitaxel YL-13027 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | NCT05138159 | Metastatic Panc... | Donafenib S1 | 18 Years - 75 Years | Fudan University | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | NCT02827201 | Metastatic Panc... | FOLFIRI.3 nab-paclitaxel+... | 18 Years - 75 Years | Federation Francophone de Cancerologie Digestive | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | NCT06411691 | Colorectal Canc... Pancreatic Canc... | KRAS Vaccine wi... Balstilimab Botensilimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | NCT04222413 | Advanced Solid ... Metastatic Panc... Pediatric Solid... Advanced Breast... Malignant Perip... Colorectal Neop... | Metarrestin | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | NCT01523457 | Metastatic Panc... Pancreatic Canc... | Folfirinox | 18 Years - | Yale University | |
| Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | NCT04212026 | Metastatic Panc... | Nivolumab | 18 Years - | University Hospital, Basel, Switzerland | |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | NCT03682289 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast... | Ceralasertib Olaparib Durvalumab | 18 Years - | University of California, San Francisco | |
| Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 | NCT01524575 | Metastatic Panc... ERCC1 | gemcitabine and... | 18 Years - | University of Hawaii | |
| Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer | NCT01273805 | Pancreatic Canc... | Hydroxychloroqu... | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Ruxolitinib in Pancreatic Cancer Patients | NCT01423604 | Pancreatic Canc... | Capecitabine Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer | NCT02109341 | Metastatic Panc... | Paclitaxel boun... | 18 Years - 75 Years | Gruppo Oncologico Italiano di Ricerca Clinica | |
| Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | NCT04672005 | Metastatic Panc... | Folfirinox alte... | 18 Years - | Rutgers, The State University of New Jersey | |
| Study of Ruxolitinib in Pancreatic Cancer Patients | NCT01423604 | Pancreatic Canc... | Capecitabine Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) | NCT00996333 | Metastatic Panc... | Gemcitabine, Do... | 18 Years - 70 Years | Columbia University | |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815 | Metastatic Panc... | Gemcitabine, na... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC | NCT06059001 | Metastatic Panc... | OMO-103 Nab-Paclitaxel Gemcitabine | 18 Years - | Peptomyc S.L. | |
| High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | NCT03008304 | Pancreatic Canc... | High-activity n... | 30 Years - 60 Years | Fuda Cancer Hospital, Guangzhou | |
| Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | NCT03929094 | Metastatic Panc... | Paclitaxel for ... Gemcitabine | 18 Years - 75 Years | Fudan University | |
| A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | NCT03721744 | Metastatic Panc... | GB201 Paclitaxel Gemcitabine Standard of car... | 18 Years - | 1Globe Biomedical Co., Ltd. | |
| Redefining FOLFIORINOX in Older Pancreatic Cancer Patients | NCT05360732 | Metastatic Panc... | FOLFIRINOX | 65 Years - | Fox Chase Cancer Center | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer | NCT01494506 | Metastatic Panc... | MM-398 5 Fluorouracil Leucovorin | 18 Years - | Merrimack Pharmaceuticals | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | NCT04799431 | Pancreatic Canc... Colorectal Canc... | Neoantigen Vacc... Retifanlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Gemcitabine and Abraxane for Pancreas Cancer | NCT02242409 | Pancreatic Canc... | Gemcitabine and... | 18 Years - | Georgetown University | |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | NCT00042939 | Pancreatic Canc... | cetuximab docetaxel irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | NCT03602885 | Metastatic Panc... Unresectable Pa... Metastatic Colo... | Usual chemother... Chemotherapy ed... | 21 Years - | Dana-Farber Cancer Institute | |
| High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | NCT03008304 | Pancreatic Canc... | High-activity n... | 30 Years - 60 Years | Fuda Cancer Hospital, Guangzhou | |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
